Feng Ye

Feng Ye


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 April 2017 in Journal of Hematology & Oncology
Verified
Journal Article
Open access
PDF file
WNWen Ni
Wen Ni
YZYuqin Zhang
Yuqin Zhang
ZZZetao Zhan
Zetao Zhan
FYFeng Ye
Feng Ye
YLYonghao Liang
Yonghao Liang
YDYi Ding
Yi Ding
Background: Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide, and tumor recurrence and metastasis are major factors that contribute to the poor outcome of patients with HCC. Long noncoding RNAs (lncRNAs) are known to regulate different tumorigenic processes, and a growing body of evidence indicates that Hippo kinase signaling is inactivated in many cancers. However, the upstream lncRNA regulators of Hippo kinase signaling in HCC are poorly understood. Methods: Using a lncRNA microarray, we identified a novel lncRNA, uc.134, whose expression was significantly decreased in the highly aggressive HCC cell line HCCLM3 compared with MHCC97L cells. Furthermore, we evaluated uc.134 expression in clinical samples using in situ hybridization (ISH) and quantitative real-time polymerase chain reaction (qRT-PCR) analysis. The full-length transcript of uc.134 was confirmed using rapid amplification of cDNA ends (RACE) analyses. To investigate the biological function of uc.134, we performed gain-of-function and loss-of-function studies both in vitro and in vivo. The underlying mechanisms of uc.134 in HCC were investigated using RNA pulldown, RNA immunoprecipitation, ubiquitination assays, Western blotting, mRNA microarray analyses, and qRT-PCR analyses. Results: The ISH assay revealed that uc.134 expression was significantly decreased in 170 paraffin-embedded samples from patients with HCC compared with adjacent tissues and uc.134 expression directly correlated with patient prognosis. Furthermore, we defined a 1867-bp full-length transcript of uc.134 using 5′- and 3′-RACE analysis. The overexpression of uc.134 inhibited HCC cell proliferation, invasion, and metastasis in vitro and in vivo, whereas the knockdown of uc.134 produced the opposite results. Furthermore, we confirmed that uc.134 (1408–1867 nt) binds to CUL4A (592–759 aa region) and inhibits its nuclear export. Moreover, we demonstrated that uc.134 inhibits the CUL4A-mediated ubiquitination of LATS1 and increases YAPS127 phosphorylation to silence the target genes of YAP. Finally, a positive correlation between uc.134, LATS1, and pYAPS127 was confirmed in 90 paraffin-embedded samples by ISH and immunohistochemical staining. Conclusions: Our study identifies that a novel lncRNA, uc.134, represses hepatocellular carcinoma progression by inhibiting the CUL4A-mediated ubiquitination of LATS1 and increasing YAPS127 phosphorylation. The use of this lncRNA may offer a promising treatment approach by inhibiting YAP and activating Hippo kinase signaling.

2 November 2022 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
YWYin Wang
Yin Wang
WZWeiwei Zeng
Weiwei Zeng
HLHuazhen Liang
Huazhen Liang
XWXixi Wu
Xixi Wu
HLHanyue Li
Hanyue Li
Lin MeiLin Mei
Lin Mei

7 May 2024 in Clinical Cancer Research
Verified
Journal Article
Open access
TTTingxi Tang
Tingxi Tang
ZZZhenhua Zhou
Zhenhua Zhou
MCMin Chen
Min Chen
NLNan Li
Nan Li
JSJianda Sun
Jianda Sun
JGJian Guan
Jian Guan
Purpose: The efficacy of induction chemotherapy (IC) as a primary treatment for advanced nasopharyngeal carcinoma (NPC) remains a topic of debate, with a lack of dependable biomarkers for predicting its efficacy. This study seeks to establish a predictive classifier using plasma metabolomics profiles. Patients and Methods: A total of 166 NPC patients enrolled in the clinical trial NCT05682703 who were undergoing IC were included in the study. Plasma lipoprotein profiles were obtained using 1H-nuclear magnetic resonance before and after IC treatment. An artificial intelligence-assisted radiomics method was developed to effectively evaluate its efficacy. Metabolic biomarkers were identified through a machine learning approach based on a discovery cohort and subsequently validated in a validation cohort that mimicked the most unfavorable real-world scenario. Results: Our research findings indicate that the effectiveness of IC varies among individual patients, with a correlation observed between efficacy and changes in metabolite profiles. Using machine learning techniques, it was determined that the extreme gradient boosting model exhibited notable efficacy, attaining an area under the curve (AUC) value of 0.792 (95% CI, 0.668–0.913). In the validation cohort, the model exhibited strong stability and generalizability, with an AUC of 0.786 (95% CI, 0.533–0.922). Conclusions: In this study, we found that dysregulation of plasma lipoprotein may result in resistance to IC in NPC patients. The prediction model constructed based on the plasma metabolites’ profile has good predictive capabilities and potential for real-world generalization. This discovery has implications for the development of treatment strategies and may offer insight into potential targets for enhancing the effectiveness of IC.

26 August 2022 in Human Cell
Verified
Journal Article
Closed access
PDF file
XWXixi Wu
Xixi Wu
YWYin Wang
Yin Wang
MYMi Yang
Mi Yang
YWYingqiao Wang
Yingqiao Wang
XWXiaoqing Wang
Xiaoqing Wang
FYFeng Ye
Feng Ye

16 April 2025 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
LZLu Zhang
Lu Zhang
LLLian Liu
Lian Liu
FLFang Li
Fang Li
PCPeijuan Chen
Peijuan Chen
FYFeng Ye
Feng Ye
This study sought to examine the current state and explore the key areas and emerging trends in radiation dermatitis prevention and management through bibliometric analysis, with the goal of providing valuable insights for future research endeavors. This study analyzed all publications on radiation dermatitis prevention and management from the Web of Science (WOS) core database up to 2024. The CiteSpace software was utilized to visualize authors, countries/regions, publishing institutions, keywords, co-cited documents, hot spots, and research frontiers. A total of 459 articles (1995–2024) were identified, with the overall number of publications demonstrating an increasing trend. The United States (125) produced the highest number of publications, followed by China (73) and Canada (45). Key research topics encompass breast cancer, head and neck cancer, acute radiation dermatitis, and radiation recall dermatitis. Double-blind clinical trials constitute the primary research methodology. The main research areas in this field focus on the role of radiotherapy dose fractionation modalities, atmospheric pressure cold plasma, hyperbaric oxygen therapy (HBOT), aloe vera, biomodulation therapy, and biological dressings in the prevention and management of radiation dermatitis. This comprehensive bibliometric analysis reveals that risk prediction, assessment tools, and the efficacy of radiodermatitis are prominent research topics in the field. These areas are currently experiencing rapid growth and warrant further attention from researchers.